Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 5 minute read Pharma Industry News Vyepti by H. Lundbeck A/S shows robust Phase IV efficacy in chronic migraine with medication-overuse headache patients H. Lundbeck A/S reports rapid and significant migraine prevention benefits for Vyepti® (eptinezumab) in Phase IV RESOLUTION trial, targeting MOH patients. byPallavi MadhirajuJune 21, 2025